Clinical proteomics in the Mann Group
One of the primary goals of the Mann Group is to discover novel blood protein biomarkers which can be used for diagnosis and possibly prevention of type 2 diabetes, obesity and other metabolic diseases.
The Mann group - Clinical Proteomics will undertake an ambitious new biomedical research programme involving proteomics of blood/plasma for patient phenotyping. The aim is to identify biological markers for diabetes, obesity and other metabolic disorders that can be used to improve diagnosis and develop more individualized therapies.
“Our eventual goal is to prevent the development of the metabolic syndrome in the first place, by targeted and personalized life style interventions,” says Professor and Group Leader, Matthias Mann.
The group will build on its world leading expertise in proteomics technologies and implement a high sensitivity and high accuracy platform to analyze the proteomics of up to 100 individuals per day at great accuracy and depth of coverage.
Together with partners at Steno Diabetes Center, Rigshospitalet, Panum Institute, the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen and elsewhere, they will apply this platform to characterize the blood proteome and how it is associated with known and novel metabolic risk factors for diabetes and cardiovascular disease.
Mass-spectrometric exploration of proteome structure and function
Ruedi Aebersold & Matthias Mann, Nature 537, 347–355 (15 September 2016) doi:10.1038/nature19949
Staff of the Mann Group
Group Leader: Professor and Research Director Matthias Mann